TG Therapeutics (NASDAQ:TGTX) Trading 7.5% Higher – Time to Buy?

TG Therapeutics, Inc. (NASDAQ:TGTX)’s stock price traded up 7.5% during mid-day trading on Thursday . The stock traded as high as $31.68 and last traded at $31.7490. 1,264,471 shares changed hands during mid-day trading, a decline of 58% from the average session volume of 3,020,441 shares. The stock had previously closed at $29.54.

More TG Therapeutics News

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Seeking Alpha published an upgrade/positive piece that highlights accelerating commercial momentum and investor “exit velocity,” supporting a more bullish growth narrative for TG Therapeutics. TG Therapeutics: The ‘Exit Velocity’ You Can’t Ignore (Rating Upgrade)
• Positive Sentiment: Media reported that Goldman Sachs sees substantial upside (~32% rally potential) as Briumvi sales accelerate, which supports a bullish case for continued revenue and earnings upside. TG Therapeutics stock pops as Briumvi boom reignites bull case: Goldman Sachs sees room for 32% rally
• Positive Sentiment: HC Wainwright raised its Q4 2025 EPS estimate to $0.27 (from $0.20) and keeps a “Buy” rating with a $60 target — a clear near?term analyst endorsement that can support upside. MarketBeat TGTX analyst note
• Positive Sentiment: HC Wainwright also raised FY2025 EPS to $2.89 (from $2.83), reflecting stronger near?term earnings expectations tied to current product momentum. MarketBeat TGTX analyst note
• Neutral Sentiment: HC Wainwright published a set of long?range forecasts (FY2026–FY2030, including FY2030 EPS of $3.96). These long?horizon numbers frame upside potential but are model?dependent and less immediately market?moving. MarketBeat TGTX analyst note
• Negative Sentiment: Bank of America Securities initiated/maintained a “Sell” on TGTX, which is directly bearish and likely pressured the stock amid mixed optimism elsewhere. TG Therapeutics (TGTX) Receives a Sell from Bank of America Securities
• Negative Sentiment: HC Wainwright trimmed several mid?to?longer?term estimates (Q4 2026, FY2026–FY2029, FY2028–FY2029 down slightly), signaling some moderation in the firm’s prior growth assumptions and reducing upside in those years despite the persistent $60 target. MarketBeat TGTX analyst note

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research note on Monday, December 29th. B. Riley upgraded TG Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 4th. The Goldman Sachs Group raised their target price on TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research note on Thursday. Wall Street Zen raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, December 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of TG Therapeutics in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $50.75.

TG Therapeutics Stock Down 0.5%

The business has a fifty day moving average price of $30.77 and a two-hundred day moving average price of $32.53. The company has a current ratio of 3.82, a quick ratio of 2.89 and a debt-to-equity ratio of 0.40. The company has a market cap of $4.85 billion, a price-to-earnings ratio of 11.00 and a beta of 1.86.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $2.19. TG Therapeutics had a net margin of 84.13% and a return on equity of 133.24%. The firm had revenue of $161.71 million for the quarter, compared to the consensus estimate of $152.12 million. During the same period in the previous year, the firm posted $0.02 earnings per share. The firm’s revenue was up 92.7% on a year-over-year basis. On average, equities analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Yann Echelard sold 5,000 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $32.57, for a total transaction of $162,850.00. Following the transaction, the director directly owned 223,816 shares of the company’s stock, valued at $7,289,687.12. This represents a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 10.64% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Johnson Financial Group Inc. acquired a new position in shares of TG Therapeutics during the second quarter valued at about $25,000. Ameritas Advisory Services LLC bought a new stake in TG Therapeutics in the second quarter valued at $25,000. Danske Bank A S acquired a new position in TG Therapeutics during the third quarter worth $25,000. Optiver Holding B.V. raised its stake in shares of TG Therapeutics by 3,485.7% in the third quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 732 shares during the last quarter. Finally, Bessemer Group Inc. grew its position in TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 486 shares during the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small?molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.